BRIEF-GSK Announces Full Results Of Positive Pivotal Phase III PIVOT-PO Trial Evaluating Tebipenem HBr

Reuters

2025/10/21

Oct 21 (Reuters) - GSK plc GSK.L & Spero Therapeutics SPRO.O :

GSK: FULL RESULTS OF POSITIVE PIVOTAL PHASE III PIVOT-PO TRIAL EVALUATING TEBIPENEM HBR
GSK: DATA SHOW TEBIPENEM HBR’S POTENTIAL AS FIRST ORAL CARBAPENEM ANTIBIOTIC FOR COMPLICATED URINARY TRACT INFECTIONS
GSK: TRIAL PRIMARY ENDPOINT MET, SHOWING NON-INFERIORITY OF ORAL TEBIPENEM HBR VERSUS IV TREATMENT
GSK: SAFETY PROFILE OF TEBIPENEM HBR GENERALLY SIMILAR TO IMIPENEM-CILASTATIN & OTHER CARBAPENEM ANTIBIOTICS
GSK: TO WORK WITH U.S. AUTHORITIES TO INCLUDE TEBIPENEM HBR DATA AS PART OF FILING IN Q4

Source text: [ID:]

Further company coverage: GSK.L

((Reuters.Briefs@thomsonreuters.com))

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2577484595"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577484595\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577484595?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-21 14:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577484595","market":"us","top_or_hot":-1,"title":"BRIEF-GSK Announces Full Results Of Positive Pivotal Phase III PIVOT-PO Trial Evaluating Tebipenem HBr","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-GSK Announces Full Results Of Positive Pivotal Phase III PIVOT-PO Trial Evaluating Tebipenem HBr</title></head><body><p><span>Oct 21 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/GLAXD\">GSK plc</a> <span>GSK.L</span> &amp; Spero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>SPRO.O</span> :</p><ul><li><p>GSK: FULL RESULTS OF POSITIVE PIVOTAL PHASE III PIVOT-PO TRIAL EVALUATING TEBIPENEM HBR</p></li><li><p>GSK: DATA SHOW TEBIPENEM HBR’S POTENTIAL AS FIRST ORAL CARBAPENEM ANTIBIOTIC FOR  COMPLICATED URINARY TRACT INFECTIONS</p></li><li><p>GSK: TRIAL PRIMARY ENDPOINT MET, SHOWING NON-INFERIORITY OF ORAL TEBIPENEM HBR VERSUS IV TREATMENT</p></li><li><p>GSK: SAFETY PROFILE OF TEBIPENEM HBR GENERALLY SIMILAR TO IMIPENEM-CILASTATIN &amp; OTHER CARBAPENEM ANTIBIOTICS</p></li><li><p>GSK: TO WORK WITH U.S. AUTHORITIES TO INCLUDE TEBIPENEM HBR DATA AS PART OF FILING IN Q4</p></li></ul><p>Source text: [ID:]</p><p>Further company coverage: <span>GSK.L</span></p><p> ((Reuters.Briefs@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-GSK Announces Full Results Of Positive Pivotal Phase III PIVOT-PO Trial Evaluating Tebipenem HBr</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-GSK Announces Full Results Of Positive Pivotal Phase III PIVOT-PO Trial Evaluating Tebipenem HBr\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-21 14:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-GSK Announces Full Results Of Positive Pivotal Phase III PIVOT-PO Trial Evaluating Tebipenem HBr</title></head><body><p><span>Oct 21 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/GLAXD\">GSK plc</a> <span>GSK.L</span> &amp; Spero <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>SPRO.O</span> :</p><ul><li><p>GSK: FULL RESULTS OF POSITIVE PIVOTAL PHASE III PIVOT-PO TRIAL EVALUATING TEBIPENEM HBR</p></li><li><p>GSK: DATA SHOW TEBIPENEM HBR’S POTENTIAL AS FIRST ORAL CARBAPENEM ANTIBIOTIC FOR  COMPLICATED URINARY TRACT INFECTIONS</p></li><li><p>GSK: TRIAL PRIMARY ENDPOINT MET, SHOWING NON-INFERIORITY OF ORAL TEBIPENEM HBR VERSUS IV TREATMENT</p></li><li><p>GSK: SAFETY PROFILE OF TEBIPENEM HBR GENERALLY SIMILAR TO IMIPENEM-CILASTATIN &amp; OTHER CARBAPENEM ANTIBIOTICS</p></li><li><p>GSK: TO WORK WITH U.S. AUTHORITIES TO INCLUDE TEBIPENEM HBR DATA AS PART OF FILING IN Q4</p></li></ul><p>Source text: [ID:]</p><p>Further company coverage: <span>GSK.L</span></p><p> ((Reuters.Briefs@thomsonreuters.com))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSK.UK","symbol_name":"葛蘭素史克","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251021:nP8N3MD0H1:1","article_id":"2577484595","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577484595","pubTimestamp":1761026407,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-GSK Announces Full Results Of Positive Pivotal Phase III PIVOT-PO Trial Evaluating Tebipenem HBrOct 21  - GSK plc GSK.L & Spero Therapeutics SPRO.O :GSK: FULL RESULTS OF POSITIVE PIVOTAL PHASE III PIVOT-PO TRIAL EVALUATING TEBIPENEM HBRGSK: DATA SHOW TEBIPENEM HBR’S POTENTIAL AS FIRST ORAL CARBAPENEM ANTIBIOTIC FOR  COMPLICATED URINARY TRACT INFECTIONSGSK: TRIAL PRIMARY ENDPOINT MET, SHOWING NON-INFERIORITY OF ORAL TEBIPENEM HBR VERSUS IV TREATMENTGSK: SAFETY PROFILE OF TEBIPENEM HBR GENERALLY SIMILAR TO IMIPENEM-CILASTATIN & OTHER CARBAPENEM ANTIBIOTICSGSK: TO WORK WITH U.S. AUTHORITIES TO INCLUDE TEBIPENEM HBR DATA AS PART OF FILING IN Q4Source text: [ID:]Further company coverage: GSK.L ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GSK.UK":"葛兰素史克","LU1670756490.USD":"ALLIANZ EUROPE INCOME AND GROWTH \"AT\" (USDHDG) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0109981661.USD":"FRANKLIN MUTUAL EUROPEAN \"A\" (USD) ACC","LU1302929846.USD":"ALLIANZ EUROPEAN EQUITY DIVIDEND \"AMG\" (USDHDG) INC","LU1400636574.HKD":"ALLIANZ EUROPE INCOME AND GROWTH \"AMG\" (HKDHDG) INC","LU1309081286.SGD":"SCHRODER ISF EUROPEAN VALUE \"A\" (SGDHDG) ACC","IE0034235071.USD":"PINEBRIDGE EUROPE RESEARCH ENHANCED EQUITY \"A\" (USD) ACC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1487256676.USD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"ZUH\" (USDHDG) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU0545562505.USD":"NINETY ONE GSF GLOBAL QUALITY DIVIDEND GROWTH \"A\" (USD) INC","LU0971552830.HKD":"ALLIANZ EUROPEAN EQUITY DIVIDEND \"AM\" (HKDHDG) INC","SPRO":"Spero Therapeutics Inc.","LU1481599808.USD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"AUC\" (USDHDG) INC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU1015430645.USD":"SCHRODER ISF UK EQUITY \"A\" (USDHDG) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1645745479.HKD":"ALLIANZ EUROPE INCOME AND GROWTH \"AM\" (HKDHDG) INC","LU0971552673.USD":"Allianz European Equity Dividend Cl AM DIS H2-USD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1202635105.USD":"ALLIANZ EUROPE INCOME AND GROWTH \"AM\" (USDHDG) INC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU1035777561.USD":"AB SICAV I - EUROPEAN EQUITY PORTFOLIO \"A\" (USDHDG) ACC","BK5011":"制药","LU1400636491.USD":"Allianz Europe Income and Growth Cl AMg DIS H2-USD","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU1098665638.USD":"FRANKLIN MUTUAL EUROPEAN \"A\" (USDHDG) H1 ACC","LU1400636657.SGD":"Allianz Europe Income and Growth Cl AMg DIS H2-SGD","LU1481600234.SGD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"ASC\" (SGDHDG) INC","BK4139":"生物科技","LU1228905037.USD":"NINETY ONE GSF GLOBAL QUALITY DIVIDEND GROWTH \"A\" (USD) ACC","IE00BQJZX424.USD":"FRANKLIN MV EUROPEAN EQUITY GROWTH AND INCOME \"A\" (USDHDG) INC","IE00BWDBJ516.SGD":"Legg Mason QS - MV European Equity Growth and Income A Mdis SGD-H Plus","LU1046248800.SGD":"Allianz European Equity Dividend Cl AM DIS H2-SGD","LU0161305163.EUR":"SCHRODER ISF EUROPEAN VALUE \"A\" (EUR) ACC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0575583348.USD":"SCHRODER ISF UK EQUITY \"A\" (USD) INC AV","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU1228905540.USD":"NINETY ONE GSF GLOBAL QUALITY DIVIDEND GROWTH \"A\" (USD) INC 2","LU1064927863.SGD":"JPMorgan Funds - Europe Dynamic A (acc) SGD-H"},"translate_title":"简介-葛兰素史克宣布评估替比培南HBr的积极关键III期PIVOT-PO试验的全部结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SPRO":0.9,"GSK.UK":0.9},"content_text":"BRIEF-GSK Announces Full Results Of Positive Pivotal Phase III PIVOT-PO Trial Evaluating Tebipenem HBrOct 21 (Reuters) - GSK plc GSK.L & Spero Therapeutics SPRO.O :GSK: FULL RESULTS OF POSITIVE PIVOTAL PHASE III PIVOT-PO TRIAL EVALUATING TEBIPENEM HBRGSK: DATA SHOW TEBIPENEM HBR’S POTENTIAL AS FIRST ORAL CARBAPENEM ANTIBIOTIC FOR  COMPLICATED URINARY TRACT INFECTIONSGSK: TRIAL PRIMARY ENDPOINT MET, SHOWING NON-INFERIORITY OF ORAL TEBIPENEM HBR VERSUS IV TREATMENTGSK: SAFETY PROFILE OF TEBIPENEM HBR GENERALLY SIMILAR TO IMIPENEM-CILASTATIN & OTHER CARBAPENEM ANTIBIOTICSGSK: TO WORK WITH U.S. AUTHORITIES TO INCLUDE TEBIPENEM HBR DATA AS PART OF FILING IN Q4Source text: [ID:]Further company coverage: GSK.L ((Reuters.Briefs@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"}}}